Asthma Therapeutics in Major Developed Markets to 2020 – Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations – Acute Market Reports

Asthma Therapeutics in Major Developed Markets to 2020 – Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

Browse Full Report Visit :- http://www.acutemarketreports.com/report/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations

Summary

GBI Research, a leading business intelligence provider, has released its latest research report,””Asthma Therapeutics in Major Developed Markets to 2020 – Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations””.The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.

 

Scope

The report covers and includes –

– An introduction to asthma, including discussion of disease epidemiology, etiology pathophysiology, symptoms, diagnosis, and treatment, with clinical data for drugs featured in the current treatment algorithm discussed in detail

– In-depth analysis of the current marketed products landscape, including product profiles of the main drugs used and heat maps that compare their safety and efficacy parameters

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches by allowing them to –

– Gain a comprehensive understanding of asthma, including diagnosis, disease severity, and treatment algorithms

– Understand the current asthma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved

– Identify trends, developments, and prominent molecule types and molecular targets within the asthma pipeline

Browse All Reports of This Category :- http://www.acutemarketreports.com/category/pharmaceutical-market

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 9
2.1 Disease Pathophysiology 9
2.1.1 Ovarian Cancer – A Group of Distinct Diseases 9
2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways 10
2.2 Symptoms and Diagnosis 12
2.3 Risk Factors 14
2.3.1 Age 14
2.3.2 Inherited Genetic Mutations 14
2.3.3 Greater Number of Lifetime Ovulations 14
2.3.4 Weight 14
2.3.5 Previous Medical Conditions 14
2.4 Treatment Algorithm 14
2.4.1 Surgery 14
2.4.2 First-Line Chemotherapy 15
2.4.3 Maintenance Therapy 18
2.5 Recurrent Disease 20

3 Marketed Products 38
3.1 Carboplatin 38
3.2 Paclitaxel 39
3.3 Gemcitabine 40
3.4 Topotecan 41
3.5 Pegylated Liposomal Doxorubicin 41
3.6 Yondelis 42
3.7 Avastin 42

To Get Complete Report @ http://www.acutemarketreports.com/report/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the worlds most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Contact Us :

Name : Chris Paul

ACUTE MARKET REPORTS

Designation : Global Sales Manager

Toll Free(US/CANADA): +1-855-455-8662

Email :  sales@acutemarketreports.com

Website : http://www.acutemarketreports.com